Business Wire

CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation... (continue reading...)

Rack-Level ZT Platform Powered by NVIDIA GB200 Grace Blackwell Superchips Enables Trillion-Parameter Inference and Training for Generative AI

SECAUCUS, N.J.--(BUSINESS WIRE)-- ZT Systems, a leading provider of accelerated computing solutions for artificial intelligence (AI) and cloud, today announced its ACX200 platform featuring the NVIDIA GB200 Grace Blackwell Superchip. Powered by NVIDIA Blackwell Tensor Core GPUs and NVIDIA Grace CPUs interconnected via... (continue reading...)

At the office opening today, Ángel Viña, CEO of Denodo will be joined by Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and representatives from Google Cloud

RIYADH, Saudi Arabia--(BUSINESS WIRE)-- Denodo, a leader in data management is opening their new Middle East regional head office in Riyadh, Kingdom of Saudi Arabia (KSA) today. To inaugurate the office opening, Denodo is launching their first “Denodo Data Day” with Her Highness Dr. Shaikha Dheya Bint... (continue reading...)

Integration enhances the Denodo Platform, providing enterprise customers with faster, more secure, and fully scalable AI capabilities

PALO ALTO, Calif.--(BUSINESS WIRE)-- Denodo, a leader in data management, announced that it has integrated NVIDIA NIM inference microservices into the Denodo Platform, as part of its focus on bolstering its rapidly expanding artificial intelligence (AI) capabilities.

The Denodo Platform's logical data management capabilities,... (continue reading...)

57% of patients treated with IMFINZI were alive at three years in ADRIATIC Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) ​demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung... (continue reading...)